Cereno Scientific (OMX: CRNO-B)

Last close As at 29/10/2025

SEK7.38

−0.10 (−1.27%)

Market capitalisation

SEK2,175m

Based in Sweden, Cereno Scientific is focused on the development of innovative, effective and safe treatments for people with rare cardiovascular and pulmonary diseases. Lead asset CS1, an HDAC inhibitor that acts as an epigenetic modulator, is currently being investigated in a Phase II clinical trial for the treatment of PAH.

Latest Insights

View More

Healthcare | edison tv

Cereno Scientific – executive interview

Healthcare | Update

Cereno Scientific — Momentum building ahead of Phase II

Healthcare | edison tv

Cereno Scientific – executive interview

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Eva Jagenheim

    CFO

  • Joakim Söderström

    Chairman

  • Sten Sörensen

    CEO

Thematics